Generics BulletinThe US Food and Drug Administration has deemed Celltrion’s Yuflyma (adalimumab-aaty) as interchangeable with the originator Humira. The interchangeability designation comes almost two years after Yufl
ScripOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo
Pink SheetOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo
Generics BulletinIf Celltrion’s US biosimilars business was already picking up speed, then that momentum is only going to continue in 2025, according to Celltrion USA’s chief commercial officer Thomas Nusbickel. In an